Breast cancer is an uncontrolled growth of breast cells. Among women, breast cancer is the second most common cancer diagnosed, after skin cancer (, and the second leading cause of cancer death, after lung cancer. In recent years, incidence rates have increased slightly (by 0.3% per year).
There are several types of breast cancer, and they are broken into two main categories: noninvasive or in situ (ductal or lobular), and invasive (ductal or lobular). In addition, breast cancer can be categorized into four molecular subtypes: a “basal-like” subgroup with low estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2) and expression of basal cytokeratins (ER-PR-HER2-); a subgroup mainly driven by HER2 amplification and overexpression while being ER/PR low (ER-PR-HER2+); a luminal A group with high ER/PR and low HER2 (ER+PR+HER2-); a luminal B group with high ER/HER2 and low PR (ER+PR-HER2+). Depending on the caner’s stage and molecular type, treatment options and prognostics of breast cancers are different: a combination of surgery, radiation therapy, chemotherapy, hormone therapy and/or administration of a targeted therapy (anti-HER2) or non-HER2 targeted therapy. Several potential targets for new breast cancer drugs have been identified in recent years. Drugs based on these targets, such as kinase inhibitors (AKT), and PD-L1, are now being studied to treat triple-negative breast cancers, either by themselves, or in combination with chemotherapy.
TargetMol’s Anti-Breast Cancer Compound Library collects 926 compounds related to breast cancer, including all reported compounds with anti-breast cancer therapeutic effect, and compounds targeting related targets in signaling pathway (HER-2, VEGF, EGFR, PARP, CDK4/6, HSP, PD-1, SET7/9, BRCA, etc.). It is a power tool for breast cancer drug discovery.
|100 μL * 10 mM (in DMSO)||13780.00|
|250 μL * 10 mM (in DMSO)||22930.00|